Miprosed (Midazolam)

Midazolam binds to the benzodiazepine site on the GABA‑A receptor, enhancing GABA‑mediated chloride influx, which hyperpolarizes neurons and suppresses excitatory activity. This potentiation produces sedation, anxiolysis, muscle relaxation and anticonvulsant effects, making it useful in various clinical settings.

The dosage of Miprosed is individualized by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and response to therapy. Only a qualified health professional should determine the appropriate dose and administration schedule.

Midazolam is classified as Pregnancy Category D, indicating evidence of risk to the fetus; it should be used only if the potential benefit justifies the risk. It is excreted in breast milk, so breastfeeding is generally not recommended while receiving the drug.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with alternatives such as diazepam or lorazepam, midazolam has a shorter onset of action and a relatively brief duration of effect when given orally, which can be advantageous for procedures requiring rapid sedation. However, its shorter half‑life may necessitate more frequent dosing for sustained control.

Miprosed should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture, light and excessive heat. Keep the product out of reach of children and do not use if the packaging is damaged.

Miprosed is supplied as an oral dosage form and is taken by mouth as directed by a healthcare professional. It may be administered with or without a small amount of water, and the tablet should be swallowed whole unless otherwise instructed.

The most critical adverse events include respiratory depression, especially when combined with other depressants, severe hypotension, paradoxical reactions such as agitation or aggression, and rare anaphylactic responses. Prompt medical attention is required if any of these symptoms occur.

Miprosed is contraindicated in patients with known hypersensitivity to midazolam or other benzodiazepines, those with acute narrow‑angle glaucoma, severe respiratory insufficiency, and individuals who are currently dependent on benzodiazepines without a supervised tapering plan. Use in pediatric populations is also generally avoided.